RECOGNITION PROGRAM
DATA COLLECTION WORKSHEET

The following data are required for each health care organization seeking recognition. This worksheet can be used to prepare for the formal data submission process. The deadline to submit 2019 data for 2020 recognition is May 29, 2020, 11:59 p.m. ET.

INSTRUCTIONS
Enter your healthcare organization’s adult (≥ 21 years) patient data for the previous calendar year. Use only numbers when entering data into the data submission platform. (No commas or decimals.)

NOTE: These data are based on MIPS Measure #438: Statin Therapy for the Prevention and Treatment of Cardiovascular Disease. Also, the AHA/ASA advocates use of ASCVD Risk Estimation tools which enables healthcare providers and patients to estimate 10-year and lifetime risk for atherosclerotic cardiovascular disease (ASCVD). You will need to provide information regarding your organization’s current use of ASCVD Risk Estimation.

ALL FIELDS ARE REQUIRED
The 2020 recognition cycle is based on the performance period of the 2019 calendar year (1/1/2019-12/31/2019).

1. What is the total adult (≥ 21 years) population for the health care organization? ____________

2. How many of your patients (≥ 21 years) are a race other than White and/or identify as Latino or Hispanic ethnicity? ____________

3. How many providers are in the health care organization? Include all physicians, nurse practitioners, and physician assistants. ____________

4. How many of your total adult (≥ 21 years) patient population are primarily attributed to the following payor groups? Sum must equal total patient count in question 1.
   _____ Medicare
   _____ Medicaid
   _____ Private Health Insurance
   _____ Other Public
   _____ Uninsured/Self-Pay
   _____ Other/Unknown

5. Does your organization currently calculate ASCVD Risk? ☐ Yes ☐ No
   If yes, where? ☐ Calculate in our EHR ☐ Clinicians calculate external to our EHR

6. Does your organization document the ASCVD Risk score? ☐ Yes ☐ No
   If yes, where? ☐ Discrete field in our EHR ☐ Notes or non-discrete field in our EHR

7. My organization is committed to continuously improving use and data capture of ASCVD Risk Estimations into our workflows and EHR systems. A “yes” response to question 7 is required for award eligibility. ☐ Yes ☐ No
8. **DENOMINATOR:**
All patients who meet one or more of the criteria below would be considered at high risk for cardiovascular events under the ACC/AHA guidelines. When reporting this measure, determine if the patient meets denominator eligibility in order of each risk category (i.e. Does the patient meet criteria #1? If not, do they meet criteria #2? If not, do they meet criteria #3?).

**How many total patients are in each high risk group? Consider all three.**

<table>
<thead>
<tr>
<th>Denominator:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients aged ≥ 21 years at the beginning of the measurement period with clinical ASCVD diagnosis.</td>
</tr>
<tr>
<td>- OR -</td>
</tr>
<tr>
<td>Patients aged ≥ 21 years at the beginning of the measurement period who have ever had a fasting or direct laboratory result of (LDL-C) level ≥ 190 mg/dL or were previously diagnosed with or currently have an active diagnosis of familial or pure hypercholesterolemia.</td>
</tr>
<tr>
<td>- OR -</td>
</tr>
<tr>
<td>Patients aged 40–75 years at the beginning of the measurement period with Type 1 or Type 2 diabetes and with a LDL-C level of 70–189 mg/dL recorded as the highest fasting or direct laboratory test results in the measurement year or during the two years prior to the beginning of the measurement period.</td>
</tr>
</tbody>
</table>

9. **NUMERATOR:** How many of these patients were prescribed or were actively using statins at any point during the measurement period?

The following section is conditional based upon the answers you provided above. You may not be prompted to answer them all in the data platform.

10. **Was the denominator (question 8 above) determined based on a subset or sample of patients in your organization?** You will need to answer if your denominator is less than 6% of your total adult population (Question 1).

   □ Yes □ No

11. **If yes, please briefly describe your sampling method and reason for sampling.**
(500 character limit)

   

12. **If no, the denominator entered in question 8 may be considered low compared to your overall population in question 1.** If the measure has been appropriately applied to all risk groups, a low denominator may be due to a unique patient population or organizational characteristics. Please describe any unique characteristics for consideration.
(500 character limit)